E-LIB Suche - Ergebnisse für: Pigeolet, Etienne

1

Population Pharmacokinetic–B Cell Modeling for Ofatumumab i..:

Yu, Huixin ; Graham, Gordon ; David, Olivier J....
CNS Drugs. 36 (2022) 3 - p. 283-300 , 2022

Link: https://doi.org/10.1007/..

2

Comparable Ofatumumab Treatment Outcomes in Patients across..:

Delgado, Silvia R. ; Williams, Mitzi J. ; Bagger, Morten...
Neurology. 96 (2021) 15_supplement - p. , 2021

Link: https://doi.org/10.1212/..

3

Dose-response analysis of ranibizumab as-needed regimens fo..:

Xiong, Yuan ; Pigeolet, Etienne ; Mulyukov, Zufar...
Contemporary Clinical Trials. 80 (2019) - p. 34-39 , 2019

Link: https://doi.org/10.1016/..

4

Neovascular Age‐Related Macular Degeneration: A Visual Acui..:

Mulyukov, Zufar ; Weber, Sebastian ; Pigeolet, Etienne...
CPT: Pharmacometrics & Systems Pharmacology. 7 (2018) 10 - p. 660-669 , 2018

Link: https://doi.org/10.1002/..

5

Reduction of a Whole-Body Physiologically Based Pharmacokin..:

Wendling, Thierry ; Tsamandouras, Nikolaos ; Dumitras, Swati...
The AAPS Journal. 18 (2015) 1 - p. 196-209 , 2015

Link: https://doi.org/10.1208/..

6

Model-Based Evaluation of the Impact of Formulation and Foo..:

Wendling, Thierry ; Ogungbenro, Kayode ; Pigeolet, Etienne...
Pharmaceutical Research. 32 (2014) 5 - p. 1764-1778 , 2014

Link: https://doi.org/10.1007/..

7

Model‐based analyses of bioequivalence crossover trials usi..:

Dubois, Anne ; Lavielle, Marc ; Gsteiger, Sandro..
Statistics in Medicine. 30 (2011) 21 - p. 2582-2600 , 2011

Link: https://doi.org/10.1002/..

8

Population Modeling of Filgrastim PK‐PD in Healthy Adults F..:

Krzyzanski, Wojciech ; Wiczling, Pawel ; Lowe, Phil...
The Journal of Clinical Pharmacology. 50 (2010) S9 - p. , 2010

Link: https://doi.org/10.1177/..

9

Population Pharmacokinetic Modelling of Filgrastim in Healt..:

Wiczling, Pawel ; Lowe, Philip ; Pigeolet, Etienne...
Clinical Pharmacokinetics. 48 (2009) 12 - p. 817-826 , 2009

Link: https://doi.org/10.2165/..

10

Bioequivalence Tests Based on Individual Estimates Using No..:

Dubois, Anne ; Gsteiger, Sandro ; Pigeolet, Etienne.
Pharmaceutical Research. 27 (2009) 1 - p. 92-104 , 2009

Link: https://doi.org/10.1007/..

11

The pharmacokinetics, CNS pharmacodynamics and adverse even..:

Rolan, Paul ; Sargentini‐Maier, Maria Laura ; Pigeolet, Etienne.
British Journal of Clinical Pharmacology. 66 (2008) 1 - p. 71-75 , 2008

Link: https://doi.org/10.1111/..

12

Population Pharmacokinetics of??Levetiracetam in Japanese a..:

Pigeolet, Etienne ; Jacqmin, Philippe ; Sargentini-Maier, Maria-Laura.
Clinical Pharmacokinetics. 46 (2007) 6 - p. 503-512 , 2007

Link: https://doi.org/10.2165/..

13

The pharmacokinetics, CNS pharmacodynamics and adverse even..:

Sargentini‐Maier, Maria Laura ; Rolan, Paul ; Connell, John...
British Journal of Clinical Pharmacology. 63 (2007) 6 - p. 680-688 , 2007

Link: https://doi.org/10.1111/..

14

Susceptibility of glutathione peroxidase to proteolysis aft..:

Pigeolet, Etienne ; Remacle, José
Free Radical Biology and Medicine. 11 (1991) 2 - p. 191-195 , 1991

Link: https://doi.org/10.1016/..

15

Alteration of enzymes in ageing human fibroblasts in cultur..:

Pigeolet, Etienne ; Remacle, José
Mechanisms of Ageing and Development. 58 (1991) 1 - p. 93-109 , 1991

Link: https://doi.org/10.1016/..